Tefibazumab, previously known as INH-H2002, represents a innovative therapeutic approach targeting complement factor H, specifically its ability to bind with C5. This antibody is engineered to inhibit the development of the C5b-9 membrane attack complex, a critical driver of cellular injury in various ailments. Early research suggest a likely role